Q32 Bio Inc., a clinical-stage biotechnology company, develops novel biologics to restore healthy immune balance in patients with autoimmune and inflammatory diseases driven by pathological immune dysfunction. The company is developing Bempikibart (ADX-914), a fully human antiinterleukin-7 receptor alpha antagonist monoclonal antibody designed to re-regulate adaptive immune function by blocking signaling mediated by interleukin-7 and thymic stromal lymphopoietin for the treatment of atopic dermatitis and alopecia areata. It also develops ADX-096, a C3d mAb CR1 fusion protein for use in ophthalmologic indications, as well as other C3d mAb fusions and nanobodies designed for tissue-targeted complement inhibition. The company was founded in 2017 and is based in Waltham, Massachusetts. Show more
Location: 830 Winter Street, Waltham, MA, 02451, United States | Website: https://www.q32bio.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
32.45M
52 Wk Range
$1.34 - $53.79
Previous Close
$3.32
Open
$2.54
Volume
4,025,424
Day Range
$2.51 - $3.08
Enterprise Value
-28.51M
Cash
65.48M
Avg Qtr Burn
-16.41M
Insider Ownership
6.57%
Institutional Own.
73.27%
Qtr Updated
03/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Bempikibart (ADX-914) Details Atopic dermatitis, Skin disease/disorder | Phase 2 Update | |
Bempikibart (ADX-914) Details Alopecia areata | Phase 2a Data readout | |
ADX-097 Details Renal disease, ANCA-Associated Vasculitis | Failed Discontinued | |
ADX-097 Details Renal disease, Lupus nephritis, IgA nephropathy, C3 Glomerulopathy | Failed Discontinued |